REACH: International prospective observational registry in patients at risk of atherothrombotic events. Results for the French arm at baseline and one year

Archives of Cardiovascular Diseases

Volumn 101, Issue 2, 2008, Pages 81-88

  Sabouret, P ^a   Cacoub, P ^a   Dallongeville, J ^b   Krempf, M ^c   Mas, J L ^d   Pinel, J F ^e   Priollets, P ^f   Steg H, G ^g   Taminau, D ^h   Montalescot, G ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d CENTRE HOSPITALIER SAINTE ANNE   (France)

^e Department of Pediatric Hematology   (France)

^f SAINT JOSEPH HOSPITAL   (France)

^g BICHAT HOSPITAL   (France)

^h Cabinet de Médecine Générale

Author keywords

Atherothrombosis; Mortality; Registry; Risk factor

Indexed keywords

ADULT; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIAC PATIENT; CARDIOVASCULAR SYMPTOM; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; FRANCE; HOSPITALIZATION; HUMAN; LEG; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MORTALITY; OBSERVATIONAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY; REGISTER; RISK FACTOR;

EID: 41549125425     PISSN: 18752136     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1875-2136(08)70263-8     Document Type: Article

References (10)

1. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.
2. The World Health Report. Reducing risks, promoting healthy lives. World Health Organization. Geneva (Switzerland); 2002.
3. Ohman EM, Bhatt DL, Steg PG, et al. The Reduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J 2006;151:e1-e10.
4. Bhatt DL, Steg PG, Ohman EM, et al. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis. JAMA 2006;295:180-9.
5. Bongard V, Cambou JP, Leizorovicz A et al. Comparaison of cardiovascular factors and drug use in 14 544 french Patients with a history of myocardial infarction, ischemic stroke and / or peripheral arterial disease. Eur J Cardiovasc Prev Rehabil 2004;11:394-402.
6. Steg PG, Bhatt DL, Wilson PWF, et al. One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis. JAMA 2007;297:1197-206.
7. Ferrières J, Cambou JP, Gayet JL et al. Prognosis of patients with atherothrombotic disease: a prospective survey in a non-hospital setting. Int J Cardiol 2006;112:302-7.
8. Sabouret P, Denolle T, Krempf M, Om S, Laville M. Enquête MICROALB :Dépistage de la microalbuminurie chez l'hypertendu diabétique de type 2 par le médecin généraliste en France métropolitaine. Arch Mal Coeur et Vaisseaux 2006;99:712-7.
9. Van Ganse E, Souchet T, Laforest L, et al Long-term achievement of the therapeutic objectives of lipid-lowering agents in primary prevention patiens and cardiovascular outcomes:an observational study. Atherosclerosis 2006;185:58-64.
10. Rothwell PM, Coull AJ, Silver LE, et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 2005;366:1773-83.